TY - JOUR

T1 - Diabetes Management in Chronic Kidney Disease

T2 - Synopsis of the 2020 KDIGO Clinical Practice Guideline

AU - Navaneethan, Sankar D

AU - Zoungas, Sophia

AU - Caramori, M Luiza

AU - Chan, Juliana C N

AU - Heerspink, Hiddo J L

AU - Hurst, Clint

AU - Liew, Adrian

AU - Michos, Erin D

AU - Olowu, Wasiu A

AU - Sadusky, Tami

AU - Tandon, Nikhil

AU - Tuttle, Katherine R

AU - Wanner, Christoph

AU - Wilkens, Katy G

AU - Lytvyn, Lyubov

AU - Craig, Jonathan C

AU - Tunnicliffe, David J

AU - Howell, Martin

AU - Tonelli, Marcello

AU - Cheung, Michael

AU - Earley, Amy

AU - Rossing, Peter

AU - de Boer, Ian H

AU - Khunti, Kamlesh

PY - 2021

Y1 - 2021

N2 - DESCRIPTION: The Kidney Disease: Improving Global Outcomes (KDIGO) organization developed a clinical practice guideline in 2020 for the management of patients with diabetes and chronic kidney disease (CKD).METHODS: The KDIGO Work Group (WG) was tasked with developing the guideline for diabetes management in CKD. It defined the scope of the guideline, gathered evidence, determined systematic review topics, and graded evidence that had been summarized by an evidence review team. The English-language literature searches, which were initially done through October 2018, were updated in February 2020. The WG used the GRADE (Grading of Recommendations Assessment, Development and Evaluation) approach to appraise evidence and rate the strength of the recommendations. Expert judgment was used to develop consensus practice points supplementary to the evidence-based graded recommendations. The guideline document underwent open public review. Comments from various stakeholders, subject matter experts, and industry and national organizations were considered before the document was finalized.RECOMMENDATIONS: The guideline includes 12 recommendations and 48 practice points for clinicians caring for patients with diabetes and CKD. This synopsis focuses on the key recommendations pertinent to the following issues: comprehensive care needs, glycemic monitoring and targets, lifestyle interventions, antihyperglycemic therapies, and educational and integrated care approaches.

AB - DESCRIPTION: The Kidney Disease: Improving Global Outcomes (KDIGO) organization developed a clinical practice guideline in 2020 for the management of patients with diabetes and chronic kidney disease (CKD).METHODS: The KDIGO Work Group (WG) was tasked with developing the guideline for diabetes management in CKD. It defined the scope of the guideline, gathered evidence, determined systematic review topics, and graded evidence that had been summarized by an evidence review team. The English-language literature searches, which were initially done through October 2018, were updated in February 2020. The WG used the GRADE (Grading of Recommendations Assessment, Development and Evaluation) approach to appraise evidence and rate the strength of the recommendations. Expert judgment was used to develop consensus practice points supplementary to the evidence-based graded recommendations. The guideline document underwent open public review. Comments from various stakeholders, subject matter experts, and industry and national organizations were considered before the document was finalized.RECOMMENDATIONS: The guideline includes 12 recommendations and 48 practice points for clinicians caring for patients with diabetes and CKD. This synopsis focuses on the key recommendations pertinent to the following issues: comprehensive care needs, glycemic monitoring and targets, lifestyle interventions, antihyperglycemic therapies, and educational and integrated care approaches.

U2 - 10.7326/M20-5938

DO - 10.7326/M20-5938

M3 - Journal article

C2 - 33166222

VL - 174

SP - 385

EP - 398

JO - Annals of Internal Medicine

JF - Annals of Internal Medicine

SN - 0003-4819

IS - 3

ER -